iMSC#3 - human sarcomasSKU: P-68

General description: 

Human mesenchymal stromal cells have extensive potential in research: uses for these including tissue repair and tissue engineering, gene therapy, the study of mesenchymal tumor oncogenes, and the analysis of cell fate determination and differentiation. The iMSC#3 cells express markers found in both primary human mesenchymal stromal cells and the multipotent form: CD90, CD44, NT5E, THY1, ENG, alanyl aminopeptidase (ANPEP), integrin beta I (ITGB1), integrin alpha 5 (ITGA5), major histocompatibililty complex, class I, A and B (HLA-A and B), and activated leukocyte cell adhesion molecule (ALCAM). These cells have also shown the ability to differentiate into adipocytes and osteoblasts. Furthermore, the cells have been verified for normal copy number, and lacks chromosomal aberrations and tumorigenicity.

The immortalized nontumorigenic iMSC#3 cell line maintains the main characteristics found in primary hMSCs, thus making this a valuable model for studying basic mesenchymal biology and differentiation, and functional studies of candidate genes involved in mesenchymal tumors.

Naderi, EH et al. "Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death." Mol Cancer 14(1):14 (2015). PubMed: PMC4323193.

Skårn, M et al. "Generation and characterization of an immortalized human mesenchymal stromal cell line." Stem Cells Dev 23(19):2377-89 (2014). PubMed: 24857590 .

About the scientist

Ola Myklebost

Senior Scientist and Group Leader at the Department of Tumor Biology, and Professor at the Department of Biosciences

Our group is using functional genomics to characterise mesenchymal oncogenesis, that is the processes leading to formation of malignant connective tissue tumours, or sarcomas. The Norwegian Radium Hospital is a national centre of competence on this kind of tumours, and our research is done in close collaboration with our clinical colleagues, both locally and within the Scandinavian Sarcoma Group. Our wider international collaborations focus on osteo- and liposarcomas. See more on and